![Hiroaki Serizawa](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profil
Hiroaki Serizawa was the founder of Coyote Pharmaceuticals, Inc. (founded in 2009) where he held the title of President & Chief Executive Officer from 2009 to 2012.
Dr. Serizawa is also the founder of AMD Therapeutics LLC.
Dr. Serizawa's former job(s) include being the Chief Executive Officer of Tor USA, Inc., Executive Director at Lifescience Catalyst Partners, Inc. in 2005, Principal at TNP Partners Corp., and Assistant Professor at the University of Kansas from 1996 to 2003.
Postes actifs de Hiroaki Serizawa
| Sociétés | Poste | Début |
|---|
Anciens postes connus de Hiroaki Serizawa
| Sociétés | Poste | Fin |
|---|---|---|
Lifescience Catalyst Partners, Inc. | Directeur/Membre du Conseil | 01/01/2005 |
University of Kansas
 University of Kansas Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 01/01/2003 |
TNP Partners Corp.
 TNP Partners Corp. Investment ManagersFinance TNP specializes in supporting venture companies. They focus on R&D-oriented companies likely to contribute to the stimulation of the local and national economy. The firm aims to create a supportive synergy between public and private sectors, assisted by the regional support platform set up by the prefectural government. They seek to establish strong relationships with research institutions, universities, and professionals engaged in entrepreneurial activities driven by science and technology. Collaboratively with TNP On The Road Corp., TNP invests in early-stage companies, with follow-up investments to foster growth or avoid dilution. They apply a business engineering approach to maximize the value of their portfolio companies. Their core portfolio consists of science and technology ventures, complemented with applied technology businesses. Their exit strategies include IPOs and mergers. | Corporate Officer/Principal | - |
Tor USA, Inc. | Directeur Général | - |
Coyote Pharmaceuticals, Inc.
 Coyote Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates a biopharmaceutical company | Fondateur | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
91
Relations au 1er degré
5
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
TNP Partners Corp.
TNP Partners Corp. Investment ManagersFinance TNP specializes in supporting venture companies. They focus on R&D-oriented companies likely to contribute to the stimulation of the local and national economy. The firm aims to create a supportive synergy between public and private sectors, assisted by the regional support platform set up by the prefectural government. They seek to establish strong relationships with research institutions, universities, and professionals engaged in entrepreneurial activities driven by science and technology. Collaboratively with TNP On The Road Corp., TNP invests in early-stage companies, with follow-up investments to foster growth or avoid dilution. They apply a business engineering approach to maximize the value of their portfolio companies. Their core portfolio consists of science and technology ventures, complemented with applied technology businesses. Their exit strategies include IPOs and mergers. | Finance |
University of Kansas
University of Kansas Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Coyote Pharmaceuticals, Inc.
Coyote Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates a biopharmaceutical company | Health Technology |
Tor USA, Inc. | |
Lifescience Catalyst Partners, Inc. |
